Gilead’s remdesivir slows progression of Covid-19 in monkeys: Study

In the study, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors.
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Updated on Jun 09, 2020 03:43 PM IST
Copy Link
Reuters | ByReuters| Posted by Susmita Pakrasi

Gilead Sciences Inc’s antiviral drug, remdesivir, prevented lung disease in macaques infected with the new coronavirus, a study published in medical journal Nature said on Tuesday.

In the study, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors.

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
OPEN APP
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Sunday, November 28, 2021